MRK | Weekly | Haru Insights

Merck KGaA (MRK) completed a $1.3 billion all-cash acquisition of Silence Therapeutics, securing Divesiran—a Phase 3-ready siRNA therapy for polycythemia vera—and marking a transformative strategic pivot away from Keytruda dependence toward RNAi therapeutics. The deal is expected to close in Q1 2027.
The upcoming earnings report on October 29, 2026, stands as the defining near-term catalyst, with consensus forecasting a 17.83% decline in EPS, a Zacks Rank of #5 (Strong Sell), and downward revisions in revenue and profit estimates—signaling intense market scrutiny.

The Silence acquisition is a bold, high-conviction move into RNAi therapeutics, placing MRK at the forefront of next-gen genetic medicine with a late-stage asset in a rare disease with severe unmet need.
The EU’s landmark approval of KEYTRUDA + Padcev for bladder cancer in all patients validates MRK’s ability to build powerful, differentiated combination therapies beyond traditional monoclonals—boosting confidence in its oncology pipeline.
Rapid integration of Mirus Bio and other bioprocessing assets is establishing MRK as a vertically integrated leader in cell and gene therapy manufacturing, offering a rare, end-to-end solution in a fragmented and capital-intensive sector.
The Semiconductor Solutions segment continues strong 17% organic growth, driven by AI demand and supply constraints—proving the business has a resilient, multi-segment growth engine that mitigates pharma-centric risks.
The aggressive but focused M&A strategy—evidenced by Silence, Bio-Techne, and SpringWorks—shows MRK is proactively building a diversified pipeline and manufacturing platform, potentially unlocking long-term structural advantages.

Merck & Co., Inc. (MRK)[Tv]